

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addiese: COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virginia 22313-1450 www.wepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/618,134	07/11/2003	Gerold Schuler	106985-2 KGB	4429	
27384 7590 02/03/2010 Briscoe, Kurt G.			EXAMINER		
Norris McLaughlin & Marcus, PA 875 Third Avenue, 8th Floor New York, NY 10022			JUEDES, AMY E		
			ART UNIT	PAPER NUMBER	
	100 1014111 10022		1644		
			MAIL DATE	DELIVERY MODE	
			02/03/2010	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/618,134	SCHULER ET AL.	
Examiner	Art Unit	
AMY E. JUEDES	1644	

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED <u>15 January 2010</u> FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.
1. The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this
application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the
application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request
for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time
periods:
a) X The period for reply expires 3 months from the mailing date of the final rejection.
b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.
Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).
Extensions of time may be obtained under 27 CER 1 126(a). The date on which the notition under 27 CER 1 126(a) and the appropriate extension fee

Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filled is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extensions he under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set for thin (b) above, if checked. A ray reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any sermed patent term adjustment. See 37 CFR 1.704(b).

NATICE OF ADDEA!

NOI	IUE	<u>UF</u>	AP	PE	<u>Αι</u>

The Notice of Appeal was filed on ______ A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(a)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).

AME	NL	IME	:NI	ıs

3.	The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because
	(a) ☑ They raise new issues that would require further consideration and/or search (see NOTE below);
	(b) ☐ They raise the issue of new matter (see NOTE below);
	(c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for
	appeal; and/or
	(d) They present additional claims without canceling a corresponding number of finally rejected claims.
	NOTE: See Continuation Sheet. (See 37 CFR 1.116 and 41.33(a)).
	The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).
5.	Applicant's reply has overcome the following rejection(s):
6.	Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).
- F	
/. L	For purposes of appeal, the proposed amendment(s): a) 🛛 will not be entered, or b) 🗌 will be entered and an explanation of
	how the new or amended claims would be rejected is provided below or appended.
	The status of the claim(s) is (or will be) as follows:
	Claim(s) allowed:
	Claim(s) objected to:
	Claim(s) rejected: 9, 11, 29-30, and 35.
	Claim(s) withdrawn from consideration: 36.
AFF	FIDAVIT OR OTHER EVIDENCE
8. [The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will <u>not</u> be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and
	was not earlier presented. See 37 CFR 1.116(e).
9. [☐ The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will <u>not</u> be entered because the affidavit or other evidence failed to overcome aff rejections under appelal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.31(d)(1).

/Amy E. Juedes/ Primary Examiner, Art Unit 1644

REQUEST FOR RECONSIDERATION/OTHER

13. Other: .

10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached.

12. Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s).

11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because:

Continuation of 3, NOTE: The proposed amendment to claim 9 to narrow the claims to anergizing with "an anergic state inducing agent consisting of" activated CD4+CD25+ T cells comprises a new issue.